Physician profile
Bethany Clary
NPI 1598732257
$1,184.78
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $921 · 2020: $210 · 2022: $14.60 · 2023: $39.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $39.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $39.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $176.98 | 2019-2020 | |
| Pfizer INC. | $175.45 | 2019-2020 | |
| Glaxosmithkline, LLC. | $146.91 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.23 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.46 | 2019-2020 | |
| Amgen INC. | $65.40 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $61.80 | 2019-2020 | |
| Novo Nordisk INC | $54.47 | 2019 | |
| Amarin Pharma, INC. | $46.00 | 2019-2020 | |
| Genentech USA, INC. | $44.95 | 2019-2020 | |
| Radius Health, INC. | $44.73 | 2019 | |
| Abbvie INC. | $39.49 | 2023 | Botox |
| Sanofi Pasteur INC. | $32.94 | 2019-2020 | |
| Lilly USA, LLC | $25.06 | 2019 | |
| Merck Sharp & Dohme LLC | $15.41 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $15.27 | 2019 | |
| Circassia INC. | $15.00 | 2020 | |
| Boston Scientific Corporation | $14.60 | 2022 | |
| Astellas Pharma US INC | $14.09 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.67 | 2019 | |
| Eisai INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Clary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.